cancer diagnosis
TK210 ELISA
AroCell
UNIBIO project
treatment response monitoring
treatment-response test
cancer screening
universal serum protein biomarker
cancer cells
cost-efficient diagnostic
TK protein
ELISA platform
plasma biomarker
malignancy potential of cancer
feasibility study
diagnostic accuracy
clinical validation
clinical utility
Phase
blood abnormal amounts of protein
invasive diagnostic procedure
cost-efficient added information
reliable biomarkers
blood sample
EU Community
effective monitoring of therapies
Current cell growth-related biomarkers
early detection of relapse
thymidine kinase
oncologists
release
rapid growth
economic viability
access
tumour tissue
knowledge
strong business opportunity
follow-up
key need of clinicians
possibility
value